Advanced delivery of biologics

Arecor for the best solution Find out more
  • Arecor for the best solution Market-Solutions/
  • Better delivery routes for liquid biological therapies Market-Solutions/hospital-home/
  • Next generation vaccines: liquid biologics without refrigeration Market-Solutions/stable-vaccines/
  • Liquid biologics for emergency use Market-Solutions/stable-liquid-formulations/
  • Market enabling solutions: labile pipeline biologics Market-Solutions/development-solutions/

About Arecor

Arecor, backed by Unilever Ventures, aims to pioneer and develop dramatically better delivery forms for proteins & biological therapies.

Find out more


  • By applying science of the highest calibre Arecor uncovers new insights in protein chemistry, enabling development of differentiating next generation biologics.

    Alan Smith, FRS CBE, Former CSO, Genzyme

  • The Arecor technology has a demonstrated potential to significantly improve the stability of complex biologicals by using novel formulation design principles.

    Bob Mattaliano, Group VP Biologics Development, Genzyme

  • Arecor has transformed the development paths and delivery options for a wide range of new therapeutic products by working closely with partner companies to employ their suite of rationally-derived stabilisation technologies.

    Andy J M Richards, Biotechnology Entrepreneur and Business Angel

  • Arecor’s biologic stabilisation technology provided the stabilisation breakthrough needed for commercialisation of Oxyzyme and Iodozyme, Archimed's unique wound healing products.

    Paul Davis, Chief Scientific Officer, Archimed LLP